01 - "Innovation Through Computer Modeling and Simulation at Medtronic"
Medtronic’s Approach to In Silico Trials
Part 1:
Title: Innovation Through Collaboration
Presenter: Markus Reiterer, Ph.D., Dist. Scientist, Corp. Science & Technology, Medtronic, PLC
Abstract:
Medtronic, a leading medical technology, company has a 70-year history of innovation. From the beginning on all innovation was founded on intense collaboration between the physician and the engineer. By disrupting ourselves we maintained leadership in several different therapy areas over decades.
Part 2:
Title: Computer Modeling as Regulatory Evidence
Presenter: Mark Palmer, M.D., Ph.D., Dist. Scientist, Corp. Science & Technology, Medtronic, PLC
Abstract:
A large portion of Medtronic’s research is focused on generating evidence for safety and efficacy and more recently also for the long-term effectiveness and economic viability of therapies we provide. Computer modeling and simulation has become an important factor in this process.
Part 3:
Title: Virtual Patients Derived from the CareLink Database
Presenter: Benymin Grosman, Ph.D., Dist. Scientist, Diabetes, Medtronic, PLC
Abstract:
The Medtronic CareLink™ database has been used to generate a total of 7485 virtual patients with known demographics for in silico trials.
Insulin action speed and meal absorption rates used in the mathematical model were validated with published literature. The virtual patients’ predictions were validated using data from the ASPIRE Clinical Trial1 and from the MiniMed™ 670G hybrid closed-loop (HCL) study
